Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000476634 | SCV000546813 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-05-20 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 407540). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. This missense change has been observed in individual(s) with prostate cancer (PMID: 33436325). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with arginine, which is basic and polar, at codon 1098 of the ATM protein (p.Gln1098Arg). |
Gene |
RCV000482771 | SCV000573400 | uncertain significance | not provided | 2023-03-02 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with prostate cancer and absent in controls (Karlsson et al., 2021); This variant is associated with the following publications: (PMID: 33436325, 19781682) |
Color Diagnostics, |
RCV000581017 | SCV000682115 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-04-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000581017 | SCV001181141 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-15 | criteria provided, single submitter | clinical testing | The p.Q1098R variant (also known as c.3293A>G), located in coding exon 22 of the ATM gene, results from an A to G substitution at nucleotide position 3293. The glutamine at codon 1098 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Institute for Clinical Genetics, |
RCV000482771 | SCV002010829 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV002248677 | SCV002516955 | uncertain significance | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003476057 | SCV004203672 | uncertain significance | Familial cancer of breast | 2023-10-30 | criteria provided, single submitter | clinical testing |